Trials / Unknown
UnknownNCT02693236
DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer
Clinical Research of Genetically Modified Dendritic Cells in Combination With Cytokine-induced Killer Cell Treatment in Middle and Advanced Esophagus Cancer Patients
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells(DC) combined with cytokine-induced killer (CIK) cells in patients with advanced esophagus cancer. Experimental recombinant adenovirus coded mRNA including MUC1 and Survivin that transfected DC, which are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the researcher plan to perform the clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adenovirus-transfected autologous DC vaccine plus CIK cells |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-08-01
- Completion
- 2016-11-01
- First posted
- 2016-02-26
- Last updated
- 2016-02-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02693236. Inclusion in this directory is not an endorsement.